Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP3A4 phenotype-based dosing of irinotecan
ISRCTN84131514Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of irinotecan in cancer (2 arms), sponsored by Erasmus MC. Primary endpoint: Primary pharmacokinetic endpoint. Started Sep 2005; status: completed.
02
Drugs
irinotecan
03
Conditions
cancer
Beyond the preview
Go deeper on ISRCTN84131514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN84131514.